Entera Bio Ltd. reported a net loss of $3.2 million, or $0.07 per ordinary share, for the three months ended September 30, 2025, compared to a net loss of $3.0 million, or $0.08 per ordinary share, for the same period in 2024. Research and development expenses rose to $1.6 million from $1.5 million, mainly due to ongoing regulatory and Phase 3 preparation activities for EB613. General and administrative expenses were $1.6 million, unchanged from the prior year period. Cash and cash equivalents stood at $16.6 million as of September 30, 2025, including $8.0 million in restricted cash for the OPKO collaboration. The company expects its cash balance to fund operations through mid-third quarter 2026. Key business developments included FDA agreement on using change in total hip bone mineral density as the primary endpoint for the planned EB613 Phase 3 study, with incidence of new or worsening vertebral fractures as a key secondary endpoint. Entera also highlighted progress on its oral GLP-2 program for short bowel syndrome and oral OXM program in obesity and metabolic diseases, in partnership with OPKO Health. The next-generation EB613 remains on track for Phase 1 initiation in late 2025.